admin – Page 8068 – Get News Story

West VA Managed IT Service Provider Discusses Cabling Design & Installation

Advantage Technology, a managed IT service provider, has recently released a new blog that details the process of cabling design and installation. The new blog was created to help customers get a look into their unique approach and processes.

Charleston, West Virginia – December 14, 2023 – Advantage Technology, a West Virginia managed IT service provider, has recently released a new article that discusses their cabling design and installation processes. The new article explains the importance of this service and how the company strives to ensure the highest level of organization and installation services. In addition, they hope that this new blog will more accurately represent these services and the attention to detail their clients have come to expect from this service.

In the new article, readers will learn about the importance of cabling and what their unique design and installation process involves. They explain the important role that cable organization and design play and how this aspect of the setup process can have a dramatic impact on longevity and efficiency. Furthermore, they also explain how structured cabling offers businesses the benefit of being adaptable and upgradeable while also saving time, money, and headaches as the need to expand may grow. With structured cabling in place, businesses can be more equipped to stay ahead of technological advancements with ease. The site provides organized and streamlined access to their technology and ensures a professional and organized infrastructure.

Advantage Technology offers companies a unique opportunity to maximize their use of technology and how they can leverage emerging methodologies to best suit their business needs. Their process is designed specifically to help companies better utilize technology to cut costs, improve efficiency, and achieve organizational goals. Their services help companies harness the ever-growing power of technology to drive growth and innovation while championing adaptability along the way. Some of the most common benefits that their clients experience include improved efficiency, streamlined processes, and an improved understanding of relevant technologies.

With the addition of this new site, Advantage Technology hopes that clients will be able to more easily learn about their cabling design and installation services and what makes their services unique. They are excited to launch the new blog and showcase the growth and development of their company. Advantage Technology is headquartered at 905 Kanawha Blvd E., Suite #100, Charleston, WV 25301. For more information on their industry-leading services, visit their website at https://www.advantage.tech/ or give them a call at 304-973-9537.

Media Contact
Company Name: Advantage Technology
Contact Person: Richard Wilbur III
Email: Send Email
Phone: 866-222-0653
Address:950 Kanawha Blvd East
City: Charleston
State: West Virginia
Country: United States
Website: https://www.advantage.tech

NigmaBot.ai Set to Launch New Generation Ai Platform

NigmaBot is the all-in-one AI powered companion for smarter seamless customized business solutions.

Miami, Florida – December 14, 2023 – The Digital Age has evolved to include Artificial Intelligence. NigmaBot.ai is set to launch the next generation of AI solutions on December 14, 2023. Artificial intelligence is the intelligence of machines or software, as opposed to the intelligence of humans or animals. It is a field of study in computer science which develops and studies intelligent machines.

NigmaBot was developed to enable business owners to transform their business with the synergy of advanced analytics for better insights. Tailor solutions effortlessly to meet its unique needs and innovate seamlessly at the intersection of AI and cloud capabilities. Artificial Intelligence enhances the speed, precision, and effectiveness of human efforts. In financial institutions, AI techniques can be used to identify which transactions are likely to be fraudulent, adopt fast and accurate credit scoring, as well as automate manually intense data management tasks.

NigmaBot many use cases:

Create attractive images using text prompts.
Internet connectivity powered AI Nigmabot.
Your own customer support agent powered by Nigmabot.
Internet scraping.
Feed content in any doc format and enhance bot’s knowledge.
Virtual assistant powered by Nigmabot.
Bulk marketing campaigns using bot.
AI powered chat in podcast.
Data entry using AI powered bot.
Write code for your ideas.
Meme generator.
Legal research.
AI Human resource.

Chat Smart, Chat Swift: Meet their AI-Powered Virtual Assistant.

Experience true advanced technology NigmaBot is designed to not have any limits in the virtual world, NigmaBot can be used in as many use cases as users may think of, try it and feel the true power of AI.

Improve ROI by 40% within 3 months of using the NigmaBot. Not sure about all of the use cases of NigmaBot? Visit the Blog Section of NigmaBot.ai

Check out upcoming Blogs:

Why Your Business Can’t Afford to Miss Out on NigmaBot.
NigmaBot: Your All-in-One AI Companion Redefining Business Possibilities.
NigmaBot: Transforming Business Landscapes Through the Power of AI.
Navigating the Social Media Jungle: The Reign of Content Marketing and the Role of NigmaBot in SEO Dominance.

For complete information, visit: https://www.nigmabot.ai/

Media Contact
Company Name: NigmaBot.ai
Contact Person: Media Relations
Email: Send Email
City: Miami
State: FL
Country: United States
Website: www.nigmabot.ai/

Ascension Coach Suzanna Kennedy Publishes a Best Selling Book for Women’s Spirituality in November 2023

Sacred Union: Ascending to a 5D Paradise by Suzanna Kennedy earns #1 New Release in Women’s Spirituality, #2 in New Age Self-Help, #5 in Women’s Spirituality.

Sacred Union: Ascending to a 5D Paradise, the much-anticipated book by renowned Ascension Coach Suzanna Kennedy, has taken the literary world by storm. The book has skyrocketed to the top of several Amazon bestseller lists, including #1 New Release in Women’s Spirituality, #2 in New Age Self-Help, and #5 in Women’s Spirituality.

In Sacred Union, Kennedy shares her personal journey of rejecting a seemingly “good life” to embark on a spiritual awakening, ultimately leading her to discover her deeper Self and embrace the interconnectedness of everything in the Universe. Packed with valuable tools and time-tested processes, this book serves as a guide to living a more fulfilling life in the emerging 5D Paradise of Oneness and Love. The tools offered in the second half of the book empower you to experience your own spiritual connection at your own pace.

Video Link: https://www.youtube.com/embed/w–cPYV7ti0

Steve Farrell, author of A New Universal Dream and co-founder and Worldwide Executive Director of Humanity’s Team, commended Kennedy’s work, stating, “Suzanna Kennedy’s book, Sacred Union: Ascending to a 5D Paradise, is a deeply important and useful book for those who are ready to awaken their deeper Self and fully engage in the interconnectedness of everything in the Universe. In addition to learning Suzanna’s story, you’ll also receive some tools and time-tested processes that will help guide you to live more fully in Oneness and Love as our 5D Paradise emerges.”

As the demand for spiritual growth and consciousness expansion continues to rise, Kennedy’s unique approach to personal growth and her transformative program, Reality Crafting 5.0 and her new Sacred Union products and services, have been making waves in the coaching and spirituality fields for over 20 years. Her remarkable insights and dedication to helping individuals tap into their higher consciousness, overcome personal barriers, and manifest their desired reality have earned her recognition as a referred service provider on Bruce Lipton’s website.

To learn more about Suzanna Kennedy’s powerful approach and to discover how her teachings and new book can profoundly impact your or your loved one’s life, visit https://www.suzannakennedy.com/

Media Contact
Company Name: Mason Works, LLC
Contact Person: Kathy Mason
Email: Send Email
Phone: 7209382536
Country: United States
Website: https://masonworksmarketing.com/

WEEX Exchange Review 2023: Empowering Global Cryptocurrency Trading

WEEX Exchange (www.weex.com) stands as a secure and compliant cryptocurrency futures trading platform. Backed by a significant investment of $100 million from a top-tier blockchain investment institution in Singapore, the exchange is on the verge of strategic investment from FSN, a Korean digital marketing giant and publicly listed company.

In addition, WEEX Exchange holds regulatory licenses from various countries and regions, including the United States MSB, Canadian MSB, and SVGFSA.

The platform caters to a user base exceeding 1 million, with a daily trading volume surpassing $1.5 billion. Presently ranking among the top 10 derivatives exchanges on CoinMarketCap and top 15 on overall global cryptocurrency exchange ranking by feixiaohao.com, WEEX is emerging as a dynamic force in the cryptocurrency exchange landscape.

WEEX App Download

WEEX App is available for download on App Store and Google Play Store in over 180 countries. It boasts one of the widest geographical coverages among cryptocurrency exchanges. Users can download and install WEEX App for iOS / Android devices from Apple App Store / Google Play Store, or through WEEX official download link. Additionally, the WEEX APK can be obtained for installation, or users can utilize Testflight for installation.

WEEX on App Store: https://apps.apple.com/us/app/weex-buy-bitcoin-crypto/id1609350789

WEEX on Google Play: https://play.google.com/store/apps/details?id=com.wake.weexprd&hl=en&gl=US

Get WEEX APK: https://support.weex.com/en/jumpdl?androidApk=Y

Download Guide：https://support.weex.com/en/jumpdl?iosAPP=Y

FSN Statement

In August 2023, FSN, the largest digital marketing group in Korea and a Kosdaq-listed company (214270.KQ), announced its plan to lead a new round of financing for WEEX on its official website. This strategic investment aims to expand WEEX’s global presence in the cryptocurrency market, enhance security for users, and strengthen global Web3 business partnerships.

Lee Sang Seok, CEO of FSN, expressed confidence in WEEX’s innovation and growth capabilities in the cryptocurrency field. Successful completion of this investment is expected to synergize with FSN’s existing Web3 business, contributing to continuous growth in technology and global reach.

Security and Compliance

WEEX Exchange has secured regulatory licenses from various countries, including the United States MSB, Canadian MSB, and SVGFSA. It is actively pursuing licenses from Australia, Philippines, Malta, and Malaysia, enhancing user trust and protection.

WEEX Protection Fund

To ensure users’ fund security, WEEX Exchange has established a 1000 BTC Protection Fund, with the fund wallet address publicly disclosed, providing users with peace of mind.

Protection Fund Wallet: https://explorer.btc.com/btc/address/bc1qufzpe776gv25v3ejv0a8vk07vhqpelql9jl0cv

Liquidity Advantage

Renowned for its trading depth, WEEX Exchange is among the world’s most liquid derivatives exchanges, ranking in the top 5 globally for CoinMarketCap’s Avg. Liquidity. The platform excels in order depth and spread, achieving millisecond-level matching, zero slippage, minimizing user trading costs and liquidity risks for an outstanding trading experience.

Futures Pro Trading

In November 2023, WEEX Exchange introduced Futures Pro Trading, supporting all USDT-M future pairs with a shared margin. This upgrade offers two order modes, “Shared (Merged)” and “Isolated (Merged),” consolidating hundreds of trading pair accounts into a Futures Pro account. The aim is to simplify and streamline user fund management and risk hedging efficiently. More updates are coming soon, such as Futures Pro copy trading.

More Special Features

WEEX Exchange provides copy trading services, allowing users to effortlessly replicate the strategies of professional traders, not only reducing entry barriers for beginners, but also enhancing trading success rates. The platform also supports Lightning Order, One Click Reversal, Ladder Force-liquidation, and other specialized features, catering to diverse and professional trading needs, enabling users to seize opportunities in rapidly changing markets.

To summarize, with safe and transparent, professional and compliant trading services, as well as advantages in order depth, copy trading, and futures pro, WEEX Exchange is rapidly rising as a dark horse in the crypto exchange field during this cycle.

This press release may contain forward-looking statements. Forward-looking statements describe future expectations, plans, results, or strategies (including product offerings, regulatory plans and business plans) and may change without notice. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements.

Media Contact
Company Name: WEEX Exchange
Email: Send Email
Country: Singapore
Website: https://www.weex.com

“Front Porches to Front Lines”: A Riveting Tale of War, Resilience, and Solidarity in Times of Crisis

Historical writer and researcher Simon I. Perlsweig announces the release of his debut novel, “Front Porches to Front Lines.” This book recounts the story of a small New England town during World War One and the 1918 Influenza Epidemic. The author will be present for a book signing event at the Miami International Book Fair on November 17, 2023.

Simon I. Perlsweig, celebrated historical writer and researcher, announces the release of his compelling debut novel, “Front Porches to Front Lines.” This captivating narrative masterfully intertwines the events of World War One and the 1918 Influenza Epidemic, detailing how they significantly impacted the American populace and shaped the twentieth century’s subsequent events.

“Front Porches to Front Lines” artfully brings to life the challenges, sacrifices, and strength of one small New England town during this tumultuous period. The community, in an extraordinary display of unity, became one of the most generous contributors to the war effort – an inspiring story of resilience that resonates even today.

Reflecting on his writing journey, Simon I. Perlsweig says, “The greatest things about being a writer are the incessant learning and discovery which comes with all the research one needs to do when writing a book. There is also a tremendous sense of satisfaction upon seeing their book get closer to being a finished product.”

Perlsweig’s work is born from his fascination with American history and his extensive research, including a family letter from Armistice Day in 1918. After completing his degree in American Studies at the University of Connecticut, his independent study project eventually blossomed into this remarkable book.

The author will make an appearance at the Miami International Book Fair. Attendees will have the opportunity to meet Perlsweig during a book signing event on November 17, 2023, at 2 p.m., where he will discuss his book and share insights into the events that inspired its creation.

“Front Porches to Front Lines” is a must-read for history enthusiasts and anyone interested in understanding the profound influence of World War One and the 1918 Influenza Epidemic on American society and the wider world.

“Front Porches to Front Lines” is available on Amazon, Barnes & Noble, and ScriptorHouse.com.

About the Book

Immerse yourself in “Front Porches to Front Lines,” a riveting tale that unfurls amidst the tumultuous backdrop of World War One and the 1918 Influenza Epidemic, twin calamities that shook the world and reshaped the twentieth century.

These global crises weren’t merely historical events that defined the 1910s but cataclysms that impacted every American. As the Great War drew to a close, the shadow of another enemy, the Spanish Influenza, loomed large, carried home by returning soldiers from the battlefields of Europe.

The heart of the narrative beats in a small New England town, a microcosm of resilience and unity in the face of these overwhelming adversities. Its citizens rallied together, their collective efforts swelling into one of the most generous contributions to the war effort. Liberty Loans, war gardens, war supplies, and even people—soldiers, Red Cross nurses, and civilian workers.

“Front Porches to Front Lines” captures this compelling story of solidarity, survival, and sacrifice, reminding us of the power of unity during the most challenging times. Step into the annals of history and experience a narrative that is as moving as it is enlightening.

About the Author

Simon I. Perlsweig is a distinguished historical writer and researcher whose debut book, “Front Porches to Front Lines,” provides a compelling account of World War One and the 1918 Influenza Epidemic. Carefully aligning with the historical significance, the book was strategically released on November 11, 2018, marking the 100th anniversary of Armistice Day and the end of the Great War.

Simon’s journey to becoming an author was unconventional, encompassing a diverse range of experiences. He initially pursued an associate’s degree and attempted a career as an architectural draftsman. Yet, his profound interest in writing led him back to academia, enrolling at the University of Connecticut to complete his bachelor’s in American Studies.

A versatile writer, Simon also dabbles in poetry, finding the genre a refreshing antidote to writer’s block. His diverse genre interests and unwavering dedication to research and discovery distinguish him as an engaging voice in historical literature.

Media Contact
Company Name: Scriptor House LLC
Email: Send Email
Country: United States
Website: scriptorhouse.com

Chronic Obstructive Pulmonary Disease Market Report 2032: Epidemiology Data, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight | Genentech, GlaxoSmithKline, Verona Pharma, Regeneron

“Chronic Obstructive Pulmonary Disease Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Chronic Obstructive Pulmonary Disease, historical and forecasted epidemiology as well as the Chronic Obstructive Pulmonary Disease market trends and analysis.

DelveInsight’s “Chronic Obstructive Pulmonary Disease Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Chronic Obstructive Pulmonary Disease, historical and forecasted epidemiology as well as the Chronic Obstructive Pulmonary Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Chronic Obstructive Pulmonary Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Chronic Obstructive Pulmonary Disease Market Forecast

Some of the key facts of the Chronic Obstructive Pulmonary Disease Market Report:

The Chronic Obstructive Pulmonary Disease market size was valued approximately USD 12 billion in 2022 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
In 2022, the number of identified cases of Chronic Obstructive Pulmonary Disease (COPD) in the 7MM was recorded at 32,796,595. It is projected that this diagnosed population of COPD within the 7MM will see a rise over the study period spanning from 2019 to 2032.
The projections indicate a greater diagnosed prevalence of COPD in the United States, reaching 18,147,244 diagnosed cases in 2022 compared to the other 7MM countries. This number is anticipated to escalate during the forecast period from 2023 to 2032
In 2022, among the five European countries assessed, Germany reported the highest diagnosed prevalent population of COPD, totaling 3,775,071 cases. Following Germany, Italy and France recorded lower figures. Conversely, Spain had the lowest diagnosed prevalent population of COPD in the same year, with 1,437,542 cases.
Key Chronic Obstructive Pulmonary Disease Companies: Genentech, Inc., GlaxoSmithKline, Verona Pharma plc, Regeneron Pharmaceuticals, Sanofi, MedImmune LLC, EpiEndo Pharmaceuticals, Tetherex Pharmaceuticals, AstraZeneca, Chiesi Farmaceutici S.p.A., Synairgen Research Ltd., Mereo Biopharma, Organicell Regenerative Medicine, Pulmotect, Inc., Inmunotek S.L., PULMATRiX, GLENMARK PHARMACEUTICALS LTD, Dimerix Limited, ProterixBio, and others
Key Chronic Obstructive Pulmonary Disease Therapies: Astegolimab (MSTT1041A, AMG 282, RG6149), SB240563 (Mepolizumab)/NUCALA, Ensifentrine (RPL554), Itepekimab/SAR440340/REGN3500, Dupilumab/SAR231893 (Dupixent), Tozorakimab (MEDI3506), FASENRA (Benralizumab), Tezspire (Tezepelumab), EP395, SelK2, Mitiperstat (AZD4831), CHF6001/Tanimilast, SNG001 (IFN-β), Acumapimod (BCT-197), Zofin, PUL-042, MV130, GSK3923868, PUR1800, GRC 39815, DMX-700, and others.
The Chronic Obstructive Pulmonary Disease epidemiology based on gender analyzed that the majority of cases of COPD are of female as compared to male, in the US
The Chronic Obstructive Pulmonary Disease market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Chronic Obstructive Pulmonary Disease pipeline products will significantly revolutionize the Chronic Obstructive Pulmonary Disease market dynamics.

Chronic Obstructive Pulmonary Disease Overview

Chronic obstructive pulmonary disease (COPD) is a widespread, treatable, and avoidable illness marked by ongoing respiratory symptoms and restricted airflow because of abnormalities in the airways or alveoli, which are typically brought on by prolonged exposure to harmful particles or gases.

Get a Free sample for the Chronic Obstructive Pulmonary Disease Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/chronic-obstructive-pulmonary-disease-copd-market

Chronic Obstructive Pulmonary Disease Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Chronic Obstructive Pulmonary Disease Epidemiology Segmentation:

The Chronic Obstructive Pulmonary Disease market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

Total Prevalence of Chronic Obstructive Pulmonary Disease
Prevalent Cases of Chronic Obstructive Pulmonary Disease by severity
Gender-specific Prevalence of Chronic Obstructive Pulmonary Disease
Diagnosed Cases of Episodic and Chronic Chronic Obstructive Pulmonary Disease

Download the report to understand which factors are driving Chronic Obstructive Pulmonary Disease epidemiology trends @ Chronic Obstructive Pulmonary Disease Epidemiology Forecast

Chronic Obstructive Pulmonary Disease Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Chronic Obstructive Pulmonary Disease market or expected to get launched during the study period. The analysis covers Chronic Obstructive Pulmonary Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Chronic Obstructive Pulmonary Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Chronic Obstructive Pulmonary Disease Therapies and Key Companies

Itepekimab/SAR440340/REGN3500: Regeneron Pharmaceuticals/Sanofi
Dupilumab/SAR231893 (Dupixent): Regeneron Pharmaceuticals/Sanofi
Tozorakimab (MEDI3506): AstraZeneca/MedImmune LLC
FASENRA (Benralizumab): AstraZeneca
Tezspire (Tezepelumab): AstraZeneca
Astegolimab (MSTT1041A, AMG 282, RG6149): Genentech, Inc.
SB240563 (Mepolizumab)/NUCALA: GlaxoSmithKline
Ensifentrine (RPL554): Verona Pharma plc
EP395: EpiEndo Pharmaceuticals
SelK2: Tetherex Pharmaceuticals
Mitiperstat (AZD4831): AstraZeneca
CHF6001/Tanimilast: Chiesi Farmaceutici S.p.A.
SNG001 (IFN-β): Synairgen Research Ltd.
Acumapimod (BCT-197): Mereo Biopharma
Zofin: Organicell Regenerative Medicine
PUL-042: Pulmotect, Inc.
MV130: Inmunotek S.L.
GSK3923868: GlaxoSmithKline
PUR1800: PULMATRiX
GRC 39815: GLENMARK PHARMACEUTICALS LTD
DMX-700: Dimerix Limited

Discover more about therapies set to grab major Chronic Obstructive Pulmonary Disease market share @ Chronic Obstructive Pulmonary Disease Treatment Landscape

Chronic Obstructive Pulmonary Disease Market Strengths

The prevalence of COPD is increasing dramatically in recent years due to the higher smoking prevalence and aging populations in many countries.

Chronic Obstructive Pulmonary Disease Market Opportunities

There is a growing demand for fixed-dose combinations as combination therapy can enhance and prolong the effects of monocomponent.

Scope of the Chronic Obstructive Pulmonary Disease Market Report

Study Period: 2019–2032
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Chronic Obstructive Pulmonary Disease Companies: Genentech, Inc., GlaxoSmithKline, Verona Pharma plc, Regeneron Pharmaceuticals, Sanofi, MedImmune LLC, EpiEndo Pharmaceuticals, Tetherex Pharmaceuticals, AstraZeneca, Chiesi Farmaceutici S.p.A., Synairgen Research Ltd., Mereo Biopharma, Organicell Regenerative Medicine, Pulmotect, Inc., Inmunotek S.L., PULMATRiX, GLENMARK PHARMACEUTICALS LTD, Dimerix Limited, ProterixBio, and others
Key Chronic Obstructive Pulmonary Disease Therapies: Astegolimab (MSTT1041A, AMG 282, RG6149), SB240563 (Mepolizumab)/NUCALA, Ensifentrine (RPL554), Itepekimab/SAR440340/REGN3500, Dupilumab/SAR231893 (Dupixent), Tozorakimab (MEDI3506), FASENRA (Benralizumab), Tezspire (Tezepelumab), EP395, SelK2, Mitiperstat (AZD4831), CHF6001/Tanimilast, SNG001 (IFN-β), Acumapimod (BCT-197), Zofin, PUL-042, MV130, GSK3923868, PUR1800, GRC 39815, DMX-700, and others
Chronic Obstructive Pulmonary Disease Therapeutic Assessment: Chronic Obstructive Pulmonary Disease current marketed and Chronic Obstructive Pulmonary Disease emerging therapies
Chronic Obstructive Pulmonary Disease Market Dynamics: Chronic Obstructive Pulmonary Disease market drivers and Chronic Obstructive Pulmonary Disease market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Chronic Obstructive Pulmonary Disease Unmet Needs, KOL’s views, Analyst’s views, Chronic Obstructive Pulmonary Disease Market Access and Reimbursement

To know more about Chronic Obstructive Pulmonary Disease companies working in the treatment market, visit @ Chronic Obstructive Pulmonary Disease Clinical Trials and Therapeutic Assessment

Table of Contents

1. Chronic Obstructive Pulmonary Disease Market Report Introduction

2. Executive Summary for Chronic Obstructive Pulmonary Disease

3. SWOT analysis of Chronic Obstructive Pulmonary Disease

4. Chronic Obstructive Pulmonary Disease Patient Share (%) Overview at a Glance

5. Chronic Obstructive Pulmonary Disease Market Overview at a Glance

6. Chronic Obstructive Pulmonary Disease Disease Background and Overview

7. Chronic Obstructive Pulmonary Disease Epidemiology and Patient Population

8. Country-Specific Patient Population of Chronic Obstructive Pulmonary Disease

9. Chronic Obstructive Pulmonary Disease Current Treatment and Medical Practices

10. Chronic Obstructive Pulmonary Disease Unmet Needs

11. Chronic Obstructive Pulmonary Disease Emerging Therapies

12. Chronic Obstructive Pulmonary Disease Market Outlook

13. Country-Wise Chronic Obstructive Pulmonary Disease Market Analysis (2019–2032)

14. Chronic Obstructive Pulmonary Disease Market Access and Reimbursement of Therapies

15. Chronic Obstructive Pulmonary Disease Market Drivers

16. Chronic Obstructive Pulmonary Disease Market Barriers

17. Chronic Obstructive Pulmonary Disease Appendix

18. Chronic Obstructive Pulmonary Disease Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Chronic Obstructive Pulmonary Disease Market Report 2032: Epidemiology Data, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight | Genentech, GlaxoSmithKline, Verona Pharma, Regeneron

ResWell Honored as a Top Workplace by Los Angeles Times for Outstanding Commitment to Workplace Culture

ResWell, the only pediatric integrative mental health practice in Pasadena, has been recognized as one of the Top Rated Workplaces in Southern California by the Los Angeles Times. This prestigious accolade places ResWell among the top 65 companies for creating a workplace culture that values diversity, equity, inclusion, and acceptance. This recognition showcases ResWell’s commitment to providing excellent patient care while fostering a nurturing and supportive environment for its team.

Dr. Francisco Navarro, Founder and CEO of ResWell, expressed his pride in this achievement: “Being recognized by the Los Angeles Times as a Top Workplace highlights our team’s dedication to creating an inclusive and empowering environment. Our success in patient care is mirrored in our collaborative workplace culture, where every team member feels valued, motivated, and highly supported.”

ResWell’s distinction as a Top Workplace is particularly notable given the comprehensive methodology used to compile the list of companies. The results came from a survey conducted with over 600 companies by DataJoe LLC and the Los Angeles Times B2B Publishing team. It evaluated each company on essential aspects like organizational health, diversity, leadership, work-life balance, and corporate social responsibility, emphasizing employee experiences and satisfaction.

“When factors such as diversity, equity, inclusion, communication and transparency from leadership, and true growth opportunities are present at a workplace, great things are bound to happen,” said the author of the Top Rated Workplaces 2023 announcement.

About the Top Rated Workplaces Award

The Top Rated Workplaces Award by the Los Angeles Times, in partnership with DataJoe LLC, is an annual recognition program highlighting the best workplaces in Southern California. The award is based on a detailed survey covering diversity, organizational health, engagement, leadership, and more. This award celebrates companies that excel in their business practices and demonstrate a profound commitment to creating healthy, inclusive, and empowering workplace cultures.

About ResWell

ResWell is the only pediatric integrative mental health practice in Pasadena. It’s home to a highly collaborative team of doctors, psychiatrists, psychologists, nurse practitioners, fitness coaches, and a clinical dietitian.

Using our team-based approach, we offer personalized treatment services in Los Angeles and the local Pasadena community that promote resilience, whole-person healing, and health optimization in daily life. We prioritize service excellence, evidence-based medicine, and coordinated treatment provided under one roof, enabling patients of all ages to thrive — now and throughout the future.

Media Contact
Company Name: ResWell
Contact Person: Risa Goldman Luksa
Email: Send Email
Phone: 626.778.0060
Address:200 E Del Mar Blvd Suite 200
City: Pasadena
State: CA 91105
Country: United States
Website: ResWellHealth.com

Neuroendocrine Tumors Pipeline Drugs Analysis Report (2023 Updates): FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Pfizer, Takeda Oncology, Hutchison MediPharma, Provectus

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Neuroendocrine Tumors pipeline constitutes 55+ key companies continuously working towards developing 60+ Neuroendocrine Tumors treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Neuroendocrine Tumors Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Neuroendocrine Tumors Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Neuroendocrine Tumors Market.

Some of the key takeaways from the Neuroendocrine Tumors Pipeline Report:

Companies across the globe are diligently working toward developing novel Neuroendocrine Tumors treatment therapies with a considerable amount of success over the years.
Neuroendocrine Tumors companies working in the treatment market are Immunomic Therapeutics, Crinetics Pharmaceuticals, Biotheus, Panavance Therapeutics, Nano Pharmaceuticals, Oxford BioTherapeutics, Seneca Therapeutics, Amgen, POINT Biopharma, RayzeBio, and others, are developing therapies for the Neuroendocrine Tumors treatment

Emerging Neuroendocrine Tumors therapies in the different phases of clinical trials are- ITI 3000, Paltusotine, PM8002, GP-2250, BG-P-TAT, OBT-620, SVV-001, Tarlatamab, PNT2003, RYZ101, and others are expected to have a significant impact on the Neuroendocrine Tumors market in the coming years.
In May 2023, Amgen commenced a Phase III study involving tarlatamab versus standard of care for individuals experiencing relapsed small cell lung cancer after initial platinum-based chemotherapy. This trial is actively enrolling participants and is projected to conclude by June 2025, aiming for an estimated enrollment of 700 participants.
In March 2023, RayzeBio, Inc., a company focused on targeted radiopharmaceuticals for solid tumors, reported the conclusion of enrollment for the Phase 1b segment within the ACTION-1 Phase 1b/3 trial evaluating RYZ101. This trial involves patients with SSTR+ gastroenteropancreatic neuroendocrine tumors (GEP-NETs) who experienced progression after receiving Lutetium-177 labeled somatostatin analog therapy.
In March 2023, NUCLIDIUM revealed that the Neuroendocrine Tumors Research Foundation (“NETRF”) has chosen the company along with its collaborative partner, the University Hospital Basel (Universitätsspital Basel, “USB”), as recipients of its Investigator Award. This funding will aid in commencing and conducting a Phase 1 clinical trial featuring TraceNETTM, an innovative copper-based radiodiagnostic tool designed for detecting neuroendocrine tumors (NET).

Neuroendocrine Tumors Overview

The specialized cells of the body’s neuroendocrine system are the starting point of a neuroendocrine cancer, also known as a neuroendocrine tumor (NET) or neuroendocrine neoplasm. These cells combine characteristics of nerve cells and endocrine cells that produce hormones.

Get a Free Sample PDF Report to know more about Neuroendocrine Tumors Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/neuroendocrine-tumors-pipeline-insight

Emerging Neuroendocrine Tumors Drugs Under Different Phases of Clinical Development Include:

ITI 3000: Immunomic Therapeutics
Paltusotine: Crinetics Pharmaceuticals
PM8002: Biotheus
GP-2250: Panavance Therapeutics
BG-P-TAT: Nano Pharmaceuticals
OBT-620: Oxford BioTherapeutics
SVV-001: Seneca Therapeutics
Tarlatamab: Amgen
PNT2003: POINT Biopharma
RYZ101: RayzeBio

Neuroendocrine Tumors Route of Administration

Neuroendocrine Tumors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

Oral
Parenteral
Intravenous
Subcutaneous
Topical.

Neuroendocrine Tumors Molecule Type

Neuroendocrine Tumors Products have been categorized under various Molecule types, such as

Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy

Neuroendocrine Tumors Pipeline Therapeutics Assessment

Neuroendocrine Tumors Assessment by Product Type
Neuroendocrine Tumors By Stage and Product Type
Neuroendocrine Tumors Assessment by Route of Administration
Neuroendocrine Tumors By Stage and Route of Administration
Neuroendocrine Tumors Assessment by Molecule Type
Neuroendocrine Tumors by Stage and Molecule Type

DelveInsight’s Neuroendocrine Tumors Report covers around 60+ products under different phases of clinical development like

Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration

Further Neuroendocrine Tumors product details are provided in the report. Download the Neuroendocrine Tumors pipeline report to learn more about the emerging Neuroendocrine Tumors therapies

Some of the key companies in the Neuroendocrine Tumors Therapeutics Market include:

Key companies developing therapies for Neuroendocrine Tumors are – Pfizer, Takeda Oncology, Hutchison MediPharma, Provectus Biopharmaceuticals, NanoValent Pharmaceuticals, Camurus, ITM Solucin, Radiomedix, Inc., Orano Med LLC, Clarity Pharmaceuticals, TaiRx, Jiangsu Hengrui Medicine, MedImmune, Genentech, Merck & Co, Peloton Therapeutics, RayzeBio, Ascentage Pharma, Debiopharm, Boehringer Ingelheim, Roche, Ipsen, Medelis Inc., Exelixis, EpicentRx, Inc., Tarveda Therapeutics, Teclison Ltd., Novatek Pharmaceuticals, Phanes Therapeutics, Fujifilm Pharmaceuticals, Jazz Pharmaceuticals, 23andMe, Inc., Celgene, Crinetics Pharmaceuticals Inc., POINT Biopharma, and others.

Neuroendocrine Tumors Pipeline Analysis:

The Neuroendocrine Tumors pipeline report provides insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Neuroendocrine Tumors with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Neuroendocrine Tumors Treatment.
Neuroendocrine Tumors key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Neuroendocrine Tumors Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Neuroendocrine Tumors market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Neuroendocrine Tumors drugs and therapies

Neuroendocrine Tumors Pipeline Market Drivers

Rising prevalence of the disease, growing Research and Development Activities are some of the important factors that are fueling the Neuroendocrine Tumors Market.

Neuroendocrine Tumors Pipeline Market Barriers

However, limited Awareness and Under diagnosis, heterogeneity and Complexity and other factors are creating obstacles in the Neuroendocrine Tumors Market growth.

Scope of Neuroendocrine Tumors Pipeline Drug Insight

Coverage: Global
Key Neuroendocrine Tumors Companies: Immunomic Therapeutics, Crinetics Pharmaceuticals, Biotheus, Panavance Therapeutics, Nano Pharmaceuticals, Oxford BioTherapeutics, Seneca Therapeutics, Amgen, POINT Biopharma, RayzeBio, and others
Key Neuroendocrine Tumors Therapies: ITI 3000, Paltusotine, PM8002, GP-2250, BG-P-TAT, OBT-620, SVV-001, Tarlatamab, PNT2003, RYZ101, and others
Neuroendocrine Tumors Therapeutic Assessment: Neuroendocrine Tumors current marketed and Neuroendocrine Tumors emerging therapies
Neuroendocrine Tumors Market Dynamics: Neuroendocrine Tumors market drivers and Neuroendocrine Tumors market barriers

Request for Sample PDF Report for Neuroendocrine Tumors Pipeline Assessment and clinical trials

Table of Contents

1. Neuroendocrine Tumors Report Introduction

2. Neuroendocrine Tumors Executive Summary

3. Neuroendocrine Tumors Overview

4. Neuroendocrine Tumors- Analytical Perspective In-depth Commercial Assessment

5. Neuroendocrine Tumors Pipeline Therapeutics

6. Neuroendocrine Tumors Late Stage Products (Phase II/III)

7. Neuroendocrine Tumors Mid Stage Products (Phase II)

8. Neuroendocrine Tumors Early Stage Products (Phase I)

9. Neuroendocrine Tumors Preclinical Stage Products

10. Neuroendocrine Tumors Therapeutics Assessment

11. Neuroendocrine Tumors Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Neuroendocrine Tumors Key Companies

14. Neuroendocrine Tumors Key Products

15. Neuroendocrine Tumors Unmet Needs

16 . Neuroendocrine Tumors Market Drivers and Barriers

17. Neuroendocrine Tumors Future Perspectives and Conclusion

18. Neuroendocrine Tumors Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Neuroendocrine Tumors Pipeline Drugs Analysis Report (2023 Updates): FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Pfizer, Takeda Oncology, Hutchison MediPharma, Provectus

DDMALL Disrupts the Video Compression Industry with Cutting-Edge Mini H.265 Encoder/Decoder Solutions

DDMALL, a global leader in video compression, announces its focus on advancing H.265 codecs worldwide. Founded in 2009 in Shenzhen, China, DDMALL pioneers miniaturized H.265 encoders and decoders.

DDMALL, a global leader in video compression technology, is proud to announce the next phase of its growth focused on accelerating the adoption of high-efficiency H.265 codecs worldwide. With over a decade of experience in research, development and manufacturing, DDMALL is committed to delivering innovative and cost-effective video compression solutions that empower customers and transform industries.

Founded in 2009 in Shenzhen, China by visionary entrepreneur Jack, DDMALL pioneered miniaturized H.265 encoders and decoders that optimize video streaming and storage. Under Jack’s leadership, DDMALL has grown into a 500-person organization with world-class R&D and manufacturing facilities. The company’s state-of-the-art headquarters feature a 10,000 square meter campus housing advanced labs, clean rooms and an AI/ML research division. DDMALL’s manufacturing plant in Dongguan spans 60,000 square meters with the capacity and certifications to produce hundreds of thousands of units per month.

DDMALL’s Innovation Engine

Over the past decade, DDMALL has invested heavily in cultivating an innovation-first company culture. The heart of DDMALL’s R&D efforts lies within its Shenzhen campus, home to over 200 engineers and researchers focused solely on next-generation video decoding compression technologies. Working closely with academic partners like Tsinghua University and Harvard, DDMALL pioneers fundamental codec architecture advances through its work in neural networks, computer vision and deep learning.

This unparalleled focus on research has fueled many industry firsts. DDMALL invented the world’s smallest single-chip H.265 encoder in 2014, measuring just 12mm x 12mm. Leveraging this expertise in miniaturization, in 2016 DDMALL commercialized the first pin-compatible H.264 to H.265 encoder upgrade modules, allowing seamless migration to higher efficiency for millions of existing products. Most recently, in 2020 DDMALL debuted the first AI-enhanced H.265 encoder capable of optimizing compression 60% better than previous solutions through real-time scene analysis and adaptive quantization.

“Our mission since day one has been to push the boundaries of video compression through cutting-edge research in AI, computer vision and new codec standards,” said Jack, Founder and CEO of DDMALL. “Today’s announcement marks an inflection point as we leverage our expertise to empower organizations across industries globally.”

Products Empowering Industries Worldwide

Leveraging its innovation engine, DDMALL offers one of the industry’s most comprehensive portfolios of H.265 products. This includes everything from single-chip mini encoders measuring just 5mm x 5mm, to rackmount encoding appliances capable of 1080p60 HD streams. DDMALL tailors its offerings to serve the unique needs of verticals like:

Surveillance: DDMALL provides the world’s smallest and most power efficient IP camera modules and NVR platforms. Products like the HDMI mini H.265 enable the next generation of AI-powered systems.
Live Streaming: As a preferred supplier to leaders like Facebook and Twitch, DDMALL enables power users to broadcast events worldwide at minimum bandwidth utilization through its ProStream family of encoders.
Video Conferencing: The CPMini265 series kits seamlessly upgrade existing conferencing hardware to H.265 without platform replacement. This eases migration to higher quality video calls.
Industrial Imaging: DDMALL’s IP65 rated XPMini265 is optimized for machine vision use cases requiring compressed video over M2M networks in harsh environments.
Storage Optimization: DDMALL compression appliances maximize usable storage space for surveillance footage archives while maintaining resolution and image quality.

This diverse product range has served tens of thousands of customers across six continents. Whether deployed standalone or integrated by OEM manufacturers, DDMALL solutions have so far optimized over 100 petabytes of video transmissions and storage worldwide.

Empowering Customers Through Accessibility

Beyond innovative products, DDMALL is committed to empowering customers through an accessible purchasing experience. With a global network of over 2000 channel partners in 130 countries, customers can obtain DDMALL solutions through their preferred resellers. In addition, DDMALL maintains localized inventory in 20 regional warehouses to ensure 95% of orders ship within 24 hours.

“Our success depends on supporting customers throughout their journeys,” said Patrick Feng, Vice President of Global Sales and Marketing. “We aim to remove barriers so video pros can focus on their core work instead of chasing suppliers. That means ensuring fast delivery, multilingual support and flexible financing options whenever needed.”

This customer-centric approach has earned DDMALL a trusted reputation. “DDMALL has enabled us to exceed bandwidth constraints and migrate 50 camera encoder to H.265 within budget,” said Fred Li, CTO at Guangzhou Smart Surveillance. “Their local inventory, financing programs and responsive technical support were crucial to the success of our transition.”

Powering the Future of Video

Looking ahead, DDMALL will continue investing $50 million annually in research and manufacturing expansion. New initiatives include hiring 100 additional engineers by 2023 focused on next-generation video coding standards like Versatile Video Coding (VVC). DDMALL will also open new offices in Seattle, Munich and Mumbai to better serve customers through localized engineering resources and channels.

“Over the next decade, global internet traffic will be dominated by video,” said Jack. “DDMALL is committed to providing the world’s most advanced and accessible video compression technologies to enable this transformation. Our goal is to help empower customers across every industry to realize the full potential of video through optimized streaming, storage and analytics.”

To learn more about DDMALL’s portfolio of innovative H.265 products and solutions, please visit www.ddmalltech.com or contact a local sales representative. Media inquiries can be directed to support@ddmall.com

Media Contact
Company Name: DDMALL Technology
Contact Person: Shirley
Email: Send Email
Phone: +86-028-60118466
Country: United States
Website: www.ddmalltech.com

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: DDMALL Disrupts the Video Compression Industry with Cutting-Edge Mini H.265 Encoder/Decoder Solutions

CharmDate Finds Millennials Are Looking for Financial Flame

“According to the results of several surveys, singles prioritize financial health over all the other factors that formerly motivated people to start new relationships.”

Ongoing economic crises caused by rising inflation, the pandemic, and other factors made singles understand the importance of finances in every aspect of their lives; including relationships. It is a dating trend on CharmDate.com that encourages singles to prioritize the importance of the financial security of their dates before going any further.

Gen Z and Millennials are looking for something more than a spark in a relationship; they are looking for a “financial flame”. It is a dating trend on CharmDate.com that encourages singles to prioritize the importance of the financial security of their dates before going any further. Ongoing economic crises caused by rising inflation, the pandemic, and other factors made singles understand the importance of finances in every aspect of their lives; including relationships.

Apart from personalities, couples should match in credit scores, bank statements, and assets, among other factors that could influence their lives economically.

How Does it Work?

Relationships that start with “financial flames” are not based on financial interest. Instead, a “financial flame” relationship starts with a mature approach between two people who don’t see the world through rose glasses, thinking that love could solve all their problems and it’s all they need to live. Many singles had problems in past relationships caused by the financial instability of their partners or they are working hard to keep up with the economic difficulties alone. For those reasons, they do not want to date someone who will turn into a burden and make their lives more difficult, especially if they are looking for serious relationships.

Finances Do Matter According to Surveys

According to the results of several surveys, singles prioritize financial health over all the other factors that formerly motivated people to start new relationships. Over 42% of the participants of the survey commissioned by Propeller Insights responded that the financial conditions of their partners are not only an important factor when seeking a potential match but they are their top priority. A survey led by a company Affirm discovered that 51% of millennial respondents listed the ability to manage money as the number one attractive trait. However, a survey from TD Bank found that 27% of its respondents talked about finances with their dates before arranging the first date.

The listed results tell us that singles are more interested in finances than they would like to admit, while a great number of them do not feel confident enough to ask questions about the topic because of the fear of seeming materialistic.

Experts Take

CharmDate experts support the maturity of discussing finances openly and understanding the importance of this topic for the further development of the relationship. If financial health is ignored at the beginning, it could be a stepping stone or even a dealbreaker later on. For that reason, it is highly recommended to accept the advantages of the ongoing dating trend. However, CharmDate professionals advise a subtle approach to it. Not everyone is following the trend and some people don’t know about it enough. For that reason, rather than asking questions before or on the first date, they recommend prioritizing personalities in relationships before gathering financial information. If someone asks direct questions about finances immediately, they might seem like they are following the “sugar relationship” more and that could drive their possible dates away. Talking enough to feel comfortable asking such questions is a better approach because it sets an example about mature relationships with great potential to succeed.

About CharmDate

CharmDate.com is an international dating site which connects singles from every corner of the world. Its mission is to provide members with a safe, easy-to-use and professional platform, and effective services including EMF Mail, Live Chat, Call, Camshare, Gifts&Flowers, etc.

CharmDate works on multiple end devices. Apart from PC and m-site, members can also download the app from Google Play Store. Dating on the go brings users a fantastic and very different experience!

Media Contact
Company Name: CharmDate
Contact Person: Media Relations
Email: Send Email
Country: HongKong
Website: http://www.charmdate.com

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: CharmDate Finds Millennials Are Looking for Financial Flame